1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Europe Human Insulin Market - Growth, Trends, and Forecast (2019 - 2024)

Europe Human Insulin Market - Growth, Trends, and Forecast (2019 - 2024)

  • May 2019
  • 79 pages
  • ID: 5778225
  • Format: PDF
  • By Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

Market Overview
The European human insulin market is expected to register a CAGR of 4.3% during the forecast period (2019-2024), and it is estimated to reach USD 4.5 billion by 2019.

- Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population levels.
- Prevalence of diabetes among all age groups in the European region is increasing mainly due to obesity, unhealthy diet and physical inactivity.
- The prevalence of autoimmune Type 1 Diabetes is also rising in Europe, and as per sources, Europe has the highest number of children with Type 1 Diabetes. The European countries that are making the most significant contribution to the overall numbers of Type 1 Diabetes in children are the United Kingdom, the Russian Federation, and Germany.
- This has resulted in a massive demand for insulin. Though Type 2 Diabetic patient’s treatment is initiated with oral drugs, insulin may also be required when glucose levels are not effectively controlled, due to the unhealthy lifestyle. Thus, a demand for insulin even exists among Type 2 Diabetic patients.

Scope of the Report
The market is segmented by Product Type (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), and Geography.

Key Market Trends
The rise in Insulin Drug Pricing

- Insulins have been in the market for decades. However, the cost of insulin has always been a primary concern.
- A recent example is the pull-out of Tresiba from Germany due to the pricing pressure after the authorities said they would price the long-acting basal insulin on par with old human insulin injections.
- Though biosimilar competition in Europe increased, allowing for insulin prices to be low, branded drugs have always been the order of the day.
- Moreover, leading players have been able to get multiple extensions by making incremental improvements to their branded drugs.

Germany Dominates the Market

- As of 2018, Germany dominated the insulin market, and it is expected to continue its dominance during the forecast period. The rise is due to the high prevalence of diabetes among the country’s population.
- In Germany, according to an estimate, the number of patients with Type 1 and Type 2 diabetes is gradually increasing.
- The diabetic population in Germany, as of 2018, was reported to be 7.9 million.
- The number is expected to increase many-fold in the coming years due to the increasing prevalence of sedentary lifestyles, changing food habits, and other lifestyle changes.

Competitive Landscape
- The European human insulin market is highly consolidated, with three major manufacturers who also have a global market presence, and the remaining manufacturers remain confined to the other local or region-specific manufacturers.
- Mergers and acquisitions between players in the recent past have helped companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Abasaglar (Insulin Glargine).
- Biocon partnered with Mylan has launched Semglee (biosimilar insulin glargine) in the European market.

Insulins Under Development:
Novo Nordisk is developing the first once-weekly long-acting insulin (LAI287), which is currently in phase 2. The insulin indicated for both Type 1 and Type 2 Diabetes patients.
Eli Lilly is developing a long-acting insulin-Fc (LY3209590). "Basal Insulin-Fc" is a large molecule comprised of engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.

Oral Insulin’s Drugs are Expected to Boost the Market:
Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of Type 1 and Type 2 Diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management.
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus, providing a more convenient, effective, as well as a safer method for delivering insulin therapy.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client’s requirements
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

($4000)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Insulin Resistance - Pipeline Review, H2 2019

Insulin Resistance - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Insulin Resistance - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H2 2019, provides an overview of the Insulin Resistance ...

Canada Diabetes Care Drugs and Devices Market - Growth, Trends, and Forecast (2019 - 2024)

Canada Diabetes Care Drugs and Devices Market - Growth, Trends, and Forecast (2019 - 2024)

  • $ 4250
  • October 2019

Market Overview- The Canada diabetes care devices market is expected to register a CAGR of about 5.9% during the forecast period (2019-2024).- Monitoring devices are anticipated to dominate the market ...

Insulin Markets in China

Insulin Markets in China

  • $ 4000
  • August 2019

China’s demand for Insulin has grown at a fast pace in the past decade.In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has ...

Bio Industry Markets in China $ 4000 October 2019


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on